Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 5-[(2-chloroethyl)(2-chloroethyl-1,1,2,2-d4)amino]-1-methyl-1H-benzimidazole-2-butanoic acid, monohydrochloride
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C16H17Cl2D4N3O2 / HCl
Formula Weight: 398.8
CAS Number: 2802569-31-7
Notes: Bendamustine-d4 is intended for use as an internal standard for the quantification of bendamustine (Item No. 23693) by GC- or LC-MS. Bendamustine is a purine analog and DNA alkylating agent.{41416} It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 μM, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 μM for both).{41417} It is cytotoxic to patient-derived lymphocytic leukemia (B-CLL) cells (LD50s = 6.8-8.3 mg/ml).{41418} Bendamustine (50 mg/kg) inhibits tumor growth by 9 and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model.{41419} It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe.{41416} Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.
English
Deutsch
